Literature DB >> 16258363

Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies.

Murielle Mimeault1, Randall E Brand, Aaron A Sasson, Surinder K Batra.   

Abstract

This review describes the recent advances in the molecular events involved in pancreatic cancer initiation, progression, and metastasis. Additionally, the importance of deregulated cellular signaling elements as potential targets for developing novel therapeutic strategies against incurable forms of pancreatic cancer is reported. The emphasis is on the critical functions gained by numerous growth factors and their receptors, such as epidermal growth factor receptor, hedgehog signaling, and proangiogenic agents such as vascular endothelial factor and interleukin-8 for the sustained growth, survival, and metastasis of pancreatic cancer cells. The molecular mechanisms associated with antitumoral properties and the clinical benefits of gemcitabine alone or in combination with other cytotoxic agents for the treatment of pancreatic cancer are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258363     DOI: 10.1097/01.mpa.0000175893.04660.1b

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  43 in total

1.  Accumulation of driver and passenger mutations during tumor progression.

Authors:  Ivana Bozic; Tibor Antal; Hisashi Ohtsuki; Hannah Carter; Dewey Kim; Sining Chen; Rachel Karchin; Kenneth W Kinzler; Bert Vogelstein; Martin A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

Review 2.  Pancreatic cancer: pathogenesis, prevention and treatment.

Authors:  Fazlul H Sarkar; Sanjeev Banerjee; Yiwei Li
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-11       Impact factor: 4.219

Review 3.  Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.

Authors:  M Mimeault; S K Batra
Journal:  Gut       Date:  2008-10       Impact factor: 23.059

4.  MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells.

Authors:  Sanjeev K Srivastava; Arun Bhardwaj; Seema Singh; Sumit Arora; Bin Wang; William E Grizzle; Ajay P Singh
Journal:  Carcinogenesis       Date:  2011-10-07       Impact factor: 4.944

Review 5.  Neurotransmitter receptors as central regulators of pancreatic cancer.

Authors:  Hildegard M Schuller; Hussein An Al-Wadei
Journal:  Future Oncol       Date:  2010-02       Impact factor: 3.404

6.  Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells.

Authors:  Imtiyaz Murtaza; Mohammad Saleem; Vaqar Mustafa Adhami; Bilal Bin Hafeez; Hasan Mukhtar
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 7.  Emergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterials.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Drug Discov Today       Date:  2012-08-10       Impact factor: 7.851

8.  Magnetic resonance imaging monitors physiological changes with antihedgehog therapy in pancreatic adenocarcinoma xenograft model.

Authors:  Alexander R Guimaraes; Elena Rakhlin; Ralph Weissleder; Sarah P Thayer
Journal:  Pancreas       Date:  2008-11       Impact factor: 3.327

Review 9.  Current update on established and novel biomarkers in salivary gland carcinoma pathology and the molecular pathways involved.

Authors:  Markus Stenner; J Peter Klussmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-12-04       Impact factor: 2.503

10.  Insulin-like growth factor binding protein-5 influences pancreatic cancer cell growth.

Authors:  Sarah K Johnson; Randy S Haun
Journal:  World J Gastroenterol       Date:  2009-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.